Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan
by Zacks Equity Research
Aerie Pharmaceuticals, (AERI) announced that it has commenced phase III study -Mercury 3 in Europe for its pipeline candidate Roclatan 0.02%/0.005%.
Allergan (AGN) Down 8.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Allergan (AGN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update
by Arpita Dutt
It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis' (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States.
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Will Conatus Key Candidate Emricasan Drive Long-Term Growth?
by Zacks Equity Research
Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.
Shire Files Marketing Application for Lifitegrast in Europe
by Zacks Equity Research
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
Are Amgen's New Drugs Doing Well Enough to Drive Sales?
by Zacks Equity Research
Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
by Zacks Equity Research
Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.
Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down
by Zacks Equity Research
Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.
Allergan (AGN) Beats Q2 Earnings & Sales; Shares Down
by Zacks Equity Research
Allergan plc (AGN) beat expectations for both earnings and sales in the second quarter. However, shares declined in pre-market trading.
5 Stocks that are Earnings All-Stars
by Tracey Ryniec
These companies have perfect, or near perfect, earnings surprise records over the last 5 years.
Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.
Allergan (AGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.
Paratek Antibiotic Candidate's Phase III Data Favorable
by Zacks Equity Research
Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod
by Zacks Equity Research
Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).
Allergan Reports Positive New Data on Irritable Bowl Drug
by Zacks Equity Research
Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).
Alkermes Presents Phase III Data on Schizophrenia Candidate
by Zacks Equity Research
Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.
Sarepta Appoints Ex-Allergan Executive as CEO and President
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).
Allergan Continues to Focus on Acquisitions and Branded Unit
by Zacks Equity Research
We issued an updated research report on Allergan plc (AGN) on Jun 23.
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
by Zacks Equity Research
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.
Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit
by Zacks Equity Research
Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.
Alkermes Gets FDA Nod for Two Month Dose of Aristada
by Zacks Equity Research
Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.